002399.SZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...

Stats
Current Price	CNY11.59
Today's Volume	2.79M
Average Volume	3.44M
Market Cap	15.33B
EPS	CNY0.380
P/E	30.50
ATR14	CNY0.0150 (0.13%)

Volume Correlation

Long: -0.98 (very strong negative)

Short: 0.11 (neutral)

Signal:(43.021) Neutral

Shenzhen Hepalink Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shenzhen Hepalink Correlation - Currency/Commodity

0.46
( neutral )

0.64
( weak )

0.00
( neutral )

-0.72
( moderate negative )

-0.23
( neutral )

0.53
( weak )

Shenzhen Hepalink Financials

Annual 2021
Revenue: CNY6.37B
Gross Profit: CNY2.03B (31.94%)
EPS: CNY0.164

Q3 2022
Revenue: CNY1.64B
Gross Profit: CNY516.22M (31.54%)
EPS: CNY0.0962

Q2 2022
Revenue: CNY1.85B
Gross Profit: CNY645.26M (34.91%)
EPS: CNY0.188

Q1 2022
Revenue: CNY1.91B
Gross Profit: CNY579.16M (30.32%)
EPS: CNY0.160

Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.